quinoxalines has been researched along with cp 481715 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brissette, WH; Brown, MF; Conklyn, MJ; DiRico, AP; Gladue, RP; Kath, JC; Lillie, BM; Lira, PD; Mairs, EN; Martin, WH; McElroy, EB; McGlynn, MA; Neote, K; Ogborne, KT; Paradis, TJ; Poss, CS; Shepard, RM; Showell, HJ; Stock, IA; Tylaska, LA | 1 |
| Cole, SH; Gladue, RP; McNeish, JD; Nelson, RT; Neote, KS; Ogborne, KT; Roach, ML; Shepard, RM; Tylaska, LA | 1 |
| Carella, AJ; Gumkowski, MJ; Lukulay, P; MacDonald, BC; Roy, MC; Shamblin, SL; Waterman, KC | 1 |
| Chow, VF; Clucas, AT; Gladue, RP; Shah, A; Zhang, YD | 1 |
| Beck, LA; Borregaard, J; Clucas, A; Skov, L; Sonne, J; Ting, N; Wang, C; Wang, L | 1 |
| Bekker, P; Dairaghi, DJ; Ertl, LS; Jaen, JC; Johnson, DA; Miao, S; Pennell, AM; Powers, JP; Schall, TJ; Seitz, LC; Wang, Y; Zeng, Y; Zhang, P | 1 |
| Ahn, J; Alley, KM; Bachovchin, KA; Fazzini, A; Gauntner, TD; Gilchrist, A; Ha, SJ; Mazzoni, MR; Merritt, JR; Pyen, DS; Sansom, SE; Willett, A; Yarfi, JL | 1 |
3 trial(s) available for quinoxalines and cp 481715
| Article | Year |
|---|---|
Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cross-Over Studies; Cyclosporine; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Fasting; Half-Life; Humans; Male; Metabolic Clearance Rate; Molecular Structure; Quinoxalines; Receptors, CCR1; Receptors, Chemokine | 2007 |
Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects.
Topics: Dermatitis, Allergic Contact; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Irritants; Male; Nickel; Quinoxalines; Receptors, CCR1 | 2008 |
Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.
Topics: Adult; Animals; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Inflammation Mediators; Male; Middle Aged; Monocytes; Protein Binding; Quinoxalines; Rabbits; Rats; Rats, Wistar; Receptors, CCR1; Young Adult | 2011 |
4 other study(ies) available for quinoxalines and cp 481715
| Article | Year |
|---|---|
CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases.
Topics: Actins; Arthritis, Rheumatoid; Calcium; CD11b Antigen; Cell Line; Chemokines; Chemotaxis; Dose-Response Relationship, Drug; Humans; Inflammation; Inhibitory Concentration 50; Kinetics; Ligands; Matrix Metalloproteinase 9; Models, Chemical; Monocytes; Protein Binding; Quinoxalines; Receptors, CCR1; Receptors, Chemokine; Signal Transduction; Transfection; Up-Regulation | 2003 |
The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice.
Topics: Actins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Migration Inhibition; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokines, CC; Chemotaxis, Leukocyte; Cytokines; Humans; Hypersensitivity, Delayed; Macrophage Inflammatory Proteins; Mice; Mice, Inbred DBA; Mice, Transgenic; Quinoxalines; Receptors, CCR1; Receptors, Chemokine; Stem Cells; Th1 Cells | 2006 |
Improved protocol and data analysis for accelerated shelf-life estimation of solid dosage forms.
Topics: Ascorbic Acid; Aspirin; Chemistry, Pharmaceutical; Dosage Forms; Drug Packaging; Drug Stability; Drug Storage; Humidity; Kinetics; Models, Chemical; Monte Carlo Method; Predictive Value of Tests; Quinoxalines; Research Design; Technology, Pharmaceutical; Temperature | 2007 |
Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
Topics: Animals; Arrestins; beta-Arrestins; Cell Line, Tumor; Chemokine CCL3; Chemotaxis; CHO Cells; Cricetulus; HEK293 Cells; Humans; Multiple Myeloma; Phenylurea Compounds; Piperidines; Quinoxalines; Radioligand Assay; Receptors, CCR1; Spiro Compounds | 2014 |